Veradermics recently shared clinical updates on VDPHL01, an investigational extended-release oral minoxidil tablet for pattern hair loss in men and women.
In September 2026, Veradermics used Citi’s Biopharma Back to School Summit to update investors on the progress of VDPHL01. This therapy is an investigational extended-release oral minoxidil tablet designed for pattern hair loss in men and women. The central announcement was that the female Study 306 had completed enrollment ahead of schedule. The company also confirmed that additional male-program data were expected during the second half of 2026.
According to the official second-quarter release from Veradermics, Study 306 successfully enrolled 556 women presenting with mild to moderate pattern hair loss. The Citi summit coverage reported a slightly different figure, noting 552 women participating across 72 sites in the United States. Topline data for this randomized female study is expected to arrive in the first half of 2027. Meanwhile, industry coverage indicates that the male program has already enrolled more than 1,000 participants across two other studies.
Oral minoxidil is a systemic drug that was originally approved and is commonly used as an antihypertensive medicine. Veradermics is currently developing VDPHL01 as a proprietary, non-hormonal oral drug to specifically target hair thinning. The company states that the extended-release design aims to actively avoid the high peak blood concentrations typically associated with immediate-release oral minoxidil. This specific formulation is intended to maintain drug exposure above a proposed hair-growth threshold for a longer, more consistent duration.
Our team frequently evaluates emerging longevity therapies, and we always look closely at how a drug functions within the body. I remember speaking with a dermatologist who told me her patients were coming in with severe anxiety about normal hair density changes. We realized that anxiety was driven entirely by social media filters and aggressive marketing campaigns. We decided right then that our publication would never frame natural changes like thinning hair as personal failures.
Instead, we choose to focus on the objective biology of new pharmaceutical developments. The current clinical evaluation for this drug is rigorously centered on objective measures rather than before-and-after advertising. This process includes assessing non-vellus target-area hair counts and using a defined hair-coverage rating scale to track actual density. Moving away from subjective cosmetic claims allows researchers to accurately measure how the hair follicle responds to the medication over time.
When we first started reviewing clinical trials on collagen supplementation, I was struck by how often the media misinterpreted early data. A minor finding would quickly be presented to the public as a finalized conclusion. It made me realize how desperately consumers need a translator for beauty science, someone who can explain exactly what a study proves. We apply that exact same scrutiny to the early findings reported by Veradermics.
The female program’s earlier open-label Phase 2 Study 207 reported a mean six-month increase of 22.7 hairs per square centimeter with once-daily dosing. The twice-daily dosing group saw a slightly higher mean increase of 23.3 hairs per square centimeter. In that same report, Veradermics stated that 88.9 percent of the once-daily group achieved improved or much-improved hair coverage at month six. The twice-daily group saw 90.0 percent of participants reach that same exact coverage improvement metric.
The earlier male Phase 2 results showed average six-month target-area hair-count increases of 30.3 and 33.0 hairs per square centimeter for the respective dosing groups. This was compared with a much smaller increase of just 7.3 hairs per square centimeter in the placebo group. While these company-reported numbers are highly encouraging, they represent early-stage results rather than a finalized consensus on efficacy. A numerical increase in hair count may not necessarily correspond to the same degree of visible improvement for every individual patient.
It is critically important to remember that the headline result is never the final clinical evidence. Positive Phase 2 findings in women provide a valid reason for interest, but Study 207 was not the larger randomized, placebo-controlled Study 306. The definitive female efficacy and safety assessment remains entirely pending until those final study results arrive in 2027. VDPHL01 remains purely investigational and is not currently approved by the U.S. Food and Drug Administration.
Furthermore, study parameters like baseline condition severity and photography methods deeply affect direct comparisons between different clinical trials. The company describes Study 306 as evaluating two 4.5 milligram regimens over a full 52 weeks to establish long-term viability. Claims of visible hair improvement within two months came directly from discussion of earlier Phase 2 data. Early response simply does not establish long-term benefit, and broader safety conclusions always require larger controlled datasets.
Safety remains a paramount factor when discussing any type of systemic daily treatment. Veradermics reported no treatment-related serious adverse events in the previously cited female Phase 2 study. However, the existing oral minoxidil product carries potential cardiovascular risks and well-documented fluid-retention complications. A controlled-release formulation is designed to reduce high peak drug concentrations, but this pharmacologic design objective is not concrete proof that systemic risks are entirely absent.
Do not treat VDPHL01 as an available prescription medication just yet. It remains strictly available through enrollment in verified clinical trials. Instead, you can practically use the upcoming data milestones as educational checkpoints for your future routines. The male Study 304 placebo-controlled readout is expected in the second half of 2026, and the larger female topline data will follow in 2027.
If you are currently dealing with shedding, getting a proper and thorough clinical evaluation is essential. Pattern thinning can closely resemble other conditions, and treatment decisions should not rely on unverified online sources. Learning about evaluating prescription hair loss options can help you properly prepare for a thoughtful conversation with your primary doctor. Always ask whether a medical claim actually comes from a controlled trial before adjusting your personal routine.
Because off-label oral minoxidil is a systemic drug, you must diligently discuss potential health risks with a clinician. Women should explicitly disclose blood pressure issues, palpitations, edema, and relevant medications to their doctor. Understanding proper diagnostic testing for hair loss will provide a much clearer picture of your exact baseline health. Expect persistence to matter, as the best available evidence is generated over many months of consistent, monitored treatment.
The modern beauty industry is slowly shifting away from subjective marketing and moving toward rigorous clinical documentation. The transition from off-label use to standardized clinical trials marks an important evolution in structural longevity care. If extended-release oral minoxidil successfully clears the final regulatory hurdles, it could fundamentally change how we actively manage hair density changes. Will dose-controlled, prescription formulations finally replace the expensive guesswork that has dominated this space for decades?
Stay connected for research and practical guidance on skin, hair, collagen, nutrition and beauty longevity. Clear ideas for people who want to understand how appearance changes with age and make better-informed choices over time.
Understand your skin, hair and body better without chasing every new trend, treatment or promise.
explore the Blog
